Signature Dx to Launch Two Colorectal Tests on Affy Platform | GenomeWeb

By Justin Petrone

German test developer Signature Diagnostics this week said it has obtained a worldwide license to use Affymetrix's GeneChip microarray platform to develop and commercialize its tests for colorectal cancer. The deal is part of Affy's 'Powered by Affymetrix' program.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.